{'fraction_non_alphanumeric': 0.02960222016651249, 'fraction_numerical': 0.009250693802035153, 'mean_word_length': 5.679012345679013, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Randomized Controlled Clinical Study of Irinotecan/cisplatin Regimen and Etoposide/cisplatin Regimen in the First-line Treatment of Small Cell Lung Cancer

Objective: This paper mainly study on the effects of irinotecan/cisplatin and etoposide/ cisplatin regimens in the treatment of small cell lung cancer. Methods: 50 cases of small cell lung cancer patients in our hospital were divided into control group and experimental group and administered with etoposide/cisplatin and irinotecan/cisplatin regimen, and the treatment effects of the two regimens were compared statistically. Results: After treatment, both groups achieved high treatment efficiency, and the incidence of toxic side effects was low, with no significant difference (P>0.05); serological ABCG2 and FGFBP1 level indicators were better than the control group, both showing significant differences (P<0.05). Conclusions: Irinotecan has achieved better improvement in serological indicators in the first-line treatment of small cell lung cancer, with no significant difference in short-term treatment efficiency.